Subcutaneous Pembrolizumab: Journal of Clinical Oncology | April 2026

Introduction

Immune checkpoint inhibitors like Pembrolizumab have transformed oncology care across multiple solid tumours. Recently, a subcutaneous (SC) formulation has been introduced using hyaluronidase technology, promising faster administration, improved patient convenience, and reduced infusion burden. This transition from intravenous (IV) to SC delivery is being positioned as a patient-centred innovation in cancer care.

Problem Statement

Despite enthusiasm, the key question remains: does SC pembrolizumab truly improve patient outcomes or system efficiency—or is it primarily a commercial strategy? Several concerns emerge:

Approval is based on pharmacokinetic non-inferiority, not clinical superiority

No meaningful improvement in survival, efficacy, or safety

Timing coincides with patent expiry, suggesting “patent hopping”

Fixed high-dose SC regimens limit:

Dose optimization

Cost-saving strategies (e.g., weight-based dosing, vial sharing)

Real-world “convenience” may be overestimated due to:

Pre-injection logistics (drug warming, scheduling)

Combination therapy with chemotherapy (no time saving)

Increased system complexity (home administration challenges)

Core issue: Is convenience being used to justify increased healthcare costs without added value?